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survival was significantly longer in HCC patients treated by 
TACE and pravastatin (20.9 months, 95% CI 15.5–26.3, p = 
0.003) than in HCC patients treated by TACE alone (12.0 
months, 95% CI 10.3–13.7).  Conclusion: Combined treat-
ment of chemoembolization and pravastatin improves sur-
vival of patients with advanced HCC in comparison to pa-
tients receiving chemoembolization alone.
 Copyright © 2008 S. Karger AG, Basel
 
 
 Hepatocellular carcinoma (HCC) is one of the most 
frequent malignancies and annually accounts for as many 
as 1 million deaths worldwide  [1–4] . Most patients have 2 
diseases – chronic liver disease and HCC – and complex 
interactions between them have major implications for 
diagnosis, prognosis and the management of HCC.
 The clinical course of patients with HCC is deter-
mined by both liver function and the extent of the HCC. 
Transarterial chemoembolization (TACE) is a minimally 
invasive procedure that has a demonstrated ability to re-
duce systemic toxicity, increase local effects and improve 
overall therapeutic results, particularly in the treatment 
of unresectable hepatocellular carcinoma  [5–10] .
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 Abstract
 Background/Aims: Pravastatin, a 3-hydroxy-3-methylgluta-
ryl coenzyme A reductase inhibitor, has been shown to in-
hibit growth and to induce apoptosis in human hepatocel-
lular carcinoma (HCC) cells. However, the potential benefit of 
pravastatin in HCC patients has still not been characterized, 
which prompted us to test the efficacy of pravastatin in pa-
tients with advanced HCC.  Methods: We investigated pro-
spectively a cohort of 183 HCC patients who had been 
 selected for palliative treatment by transarterial chemo-
embolization (TACE). Fifty-two patients received TACE com-
bined with pravastatin (20–40 mg/day) and 131 patients 
 received chemoembolization alone. Six independent pre-
dictors of survival according to the Vienna survival model for 
HCC were equally distributed in both groups.  Results: Dur-
ing the observation period of up to 5 years, 31 (23.7%) out of 
131 patients treated by TACE alone and 19 (36.5%) out of 52 
patients treated by TACE and pravastatin survived. Median 
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 In addition to their cholesterol-lowering effects, statins 
such as fluvastatin and pravastatin inhibit tumor cell 
growth  [11–14] . More recently it was demonstrated that 
pravastatin reduces progression and limits metastatic 
diffusion in a rat model of very aggressive HCC  [15] . A 
clinical study by Kawata et al.  [16] , the only one conduct-
ed so far, showed that pravastatin prolongs survival of 
patients with advanced HCC when applied after treat-
ment with TACE and oral 5-fluorouracil. Nevertheless, 
the benefit of pravastatin in HCC patients has still not 
been characterized, which prompted us to test the effi-
cacy of pravastatin in a large cohort of patients with ad-
vanced HCC who had been selected for TACE.
 Patients and Methods
 Our prospective cohort included 183 HCC patients (149 males 
and 34 females, mean age 64  8 10 years) who were diagnosed and 
staged in our institution between 2003 and 2008. Patients with 
early HCC (1 nodule  ! 5 cm or 3 nodules  ! 3 cm each) and im-
paired liver function who were considered for orthotopic liver 
transplantation were not evaluated in this investigation. 
 To address the problem of selection bias we determined in the 
cohort of 183 HCC-patients 6 independent predictors of survival. 
These included bilirubin ( 1 2 mg/dl), portal vein thrombosis, pro-
thrombin time ( ! 70%),   -fetoprotein (AFP,  1 125 kU/l), tumor 
mass  1 50% and enlarged lymph nodes, according to the Vienna 
survival model for HCC (VISUM-HCC)  [17] .
 Prior to therapy, 138 HCC patients presented with VISUM 
stage 1 (0–2 points), while 30 patients were classified as stage 2 (3 
points) and 15 patients as stage 3 (4–6 points). 
 All patients selected for TACE had advanced HCC and did not 
fit into the surgical criteria either for resection (due to bilateral 
disease, inoperability due to cardiopulmonary risk factors, unre-
sectability due to proximity of the tumors to large vessels or im-
paired liver function) or liver transplantation (according to the 
Milan criteria:  fewer than 3 nodules  ! 3 cm in diameter or a single 
HCC  ! 5 cm in diameter) or for combined treatment with chemo-
embolization and radiofrequency ablation (tumor size  ! 5 cm, 
fewer than 4–5 tumor nodules, no significant extrahepatic 
spread).
 Disease extension was assessed using ultrasound, computed 
tomography (CT) and magnetic resonance imaging.
 Diagnosis of HCC was confirmed via needle biopsy or via ra-
diological criteria (2 coincident imaging techniques) or combined 
criteria (1 imaging technique associated with elevated AFP levels 
according to the Barcelona EASL Conference 2000  [18] ). Written 
informed consent was obtained from each patient and the study 
protocol conformed to the ethical guidelines of the 1975 Declara-
tion of Helsinki, as reflected in a priori approval by the institu-
tional review committee. 
 Treatment Procedures
 Transarterial  Chemoembolization . Patients not suitable for 
surgery or combined treatment with TACE and radiofrequency 
ablation were considered for chemoembolization alone. Patients 
with multifocal large ( 1 8 cm tumor nodules) and diffuse growing 
tumors were not included for TACE.
 All TACE procedures were performed under angiographic 
control (Multistar TOP and Axiom Artis dTA, Siemens, Munich, 
Germany) and under local anesthesia. After inserting a 4-Fr pig-
tail catheter into the femoral artery via a microincision in the 
groin, a panviscerography was performed to detect potential ab-
errant or additional hepatic and possibly tumor-feeding arteries. 
After identifying the tumor-feeding arteries, a 4-Fr catheter (e.g. 
cobra configuration) for selective use or a superselective micro-
catheter, which could be placed through the primary 4-Fr cathe-
ter, were directed as close as possible to the tumor-feeding vessels. 
The embolizing moiety was prepared by extensive mixing be-
tween 2 syringes, typically 3–5 ml lipiodol, microparticles of 150–
500   m (e.g. Contour SE  , Boston Scientific, Ratingen, Germany) 
and farmorubicin (1 mg/kg b.w.). The embolizing agent was then 
injected slowly under fluoroscopic control to avoid retrograde 
embolization of nontarget areas due to back spill. As soon as sta-
sis within the tumor vessels occurred, the injection was stopped. 
Treatment was terminated if, over 5–10 min, a flow within the 
tumor vessels was no longer detectable. Otherwise another injec-
tion was performed. In cases of several main feeders these vessels 
were treated subsequently.
 One day after the procedure a baseline CT was performed to 
document the storage of the embolizing agent within the tumor. 
Follow-up studies by triphasic (native, arterial and portal-venous) 
contrast-enhanced CT were performed incorporating the general 
clinical situation of the patient 6–12 weeks after the initial proce-
dure, and a new TACE was performed if there were signs of ‘de-
storage’ with revascularization of the treated tumor, or if new tu-
mors were detected. 
 Systemic Therapy with Pravastatin . Fifty-two HCC patients 
(41 men and 11 women, mean age 66  8 10 years) received 20–40 
mg pravastatin as a single dose daily in addition to chemoembo-
lization. 
 Follow-Up and Statistical Analysis
 Survival was set as the primary endpoint of the study. Follow-
up every 3–6 months was computed as starting from the begin-
ning of the treatment and was maintained until death or the last 
visit before March 2008. Patients received clinical examination, 
blood analysis including AFP and imaging techniques (ultra-
sound, spiral CT or magnetic resonance imaging alternatively). 
Upon detection of treatment failure or recurrence, patients were 
considered for new treatment sessions. 
 Probability curves obtained via the Kaplan-Meier method 
were compared using the log rank test, and for group comparisons 
the   2 and Mann-Whitney tests were performed. 
 Calculations were done with SPSS package (SPSS Inc., Chica-
go, Ill., USA) and the level of significance was set at p  ! 0.05.
 Results
 Table 1 depicts the characteristics of the 2 groups of 
HCC patients. No significant difference between the 2 
groups was detected concerning age, sex, etiology of liver 
cirrhosis, VISUM score, AFP, presence of portal-vein 
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thrombosis, bilirubin levels, prothrombin times and the 
number of TACE treatments. Enlarged perihepatic lymph 
nodes were significantly (p = 0.016) more frequent in 
HCC patients treated with TACE and pravastatin. Fur-
thermore,  table 1 illustrates survival time (median and 
95% CI) in the 183 patients with HCC who received TACE 
alone or TACE combined with pravastatin. During the 
observation period of up to 5 years, 31 (23.7%) out of 131 
patients treated by TACE alone and 19 (36.5%) out of 52 
patients treated by TACE and pravastatin survived.
 Statistical analysis showed a significantly (p = 0.003) 
improved survival time in the subgroup of patients treat-
ed with chemoembolization and pravastatin (median 
20.9 months, 95% CI 15.5–26.3) compared to patients 
treated with chemoembolization alone (median 12.0 
months, 95% CI 10.3–13.7).
 Kaplan-Meier plots of the 2 groups of HCC patients 
are illustrated in  figure 1 and demonstrate the marked 
survival benefit to HCC patients of treatment with che-
moembolization combined with pravastatin as compared 
to chemoembolization alone.
 Discussion
 The management of HCC has improved in recent 
years. However, many treatments for HCC have only lim-
ited impact on outcome since most patients with HCC 
suffer from 2 diseases: chronic liver disease, usually at the 
stage of cirrhosis, and HCC  [19] . Thus, both the extent of 
HCC and the grade of liver dysfunction affect the prog-
nosis of HCC patients. Therefore, most prognostic scores 
include parameters of liver function.
 An independent evaluation of prognostic scores in a 
Central European cohort of patients with HCC has been 
 Table 1. Characteristics of 183 HCC patients prior to treatment 
with TACE alone or TACE and pravastatin
 Variables TACE 
alone 
TACE and 
pravastatin 
 p 
 Age 63 8 10 66 8 10  0.101 
 Sex (M/F) 108/23 41/11  0.574 
 Etiology 
 HCV 32 9 
 HBV 10 3 
 Alcohol 42 17 
 Other 36 19 
 Mixed 11 4 
 VISUM score  0.239 
0–2 102 36 
3 19 11 
4–6 10 5 
 Bilirubin, mg/dl 1.8 8 1.4 1.6 8 1.2  0.284 
 Bilirubin   0.691 
 ≤2 mg/dl 97 37 
 >2 mg/dl 34 15 
 Prothrombin act, %  75.1 8 14.4  76.6 8 14.0  0.590 
 Prothrombin act  0.797 
 >70% 83 34 
 ≤70% 48 18 
 AFP   0.565 
 ≤125 kU/l 81 30 
 >125 kU/l 50 22 
 Portal vein thrombosis  0.741 
 Yes 13 4 
 No 118 48 
 Enlarged lymph nodes  0.016 
 Yes 27 20 
 No 104 32 
 Tumor size   0.960 
 ≤50% 70 28 
 >50% 61 24 
 Number of TACE 4.2 8 3.8 4.2 8 2.7 
 Median survival time, months  12.0  20.9 
 95% CI  10.3 4 13.7  15.5 4 26.3 
 HBV = Hepatitis B virus; HCV = hepatitis C virus.  
1.0
C
u
m
u
la
ti
v
e
su
rv
iv
a
l
0.8
0.6
0.4
0.2
0
0 10 20 30 40 50 60 70
Survival time (months)
TACE
TACE + pravastatin
 Fig. 1. Survival rates determined by Kaplan-Meier of HCC pa-
tients treated by combined TACE and pravastatin (n = 52) or 
TACE alone (n = 131). Statistical evaluation by log rank test 
showed an improved survival of patients treated by TACE and 
pravastatin compared to TACE alone (p = 0.003). 
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presented recently  [20] . The Child-Turcotte-Pugh score, 
Okuda score, VISUM-HCC score, Chevret score, Barce-
lona clinic liver cancer classification and cancer of the 
liver Italian program score were calculated. All scores 
performed similarly to the Okuda score in the receiver 
operating characteristic analysis.
 In our prospective study we used the new VISUM-
HCC survival model  [17] to characterize the cohorts of 
patients who had received treatment by chemoemboliza-
tion alone or chemoembolization and pravastatin. The 6 
independent predictors of survival according to VISUM-
HCC were equally distributed in both groups ( table 1 ). 
However, the main problem of our study is that it is not 
randomized or blinded. Indeed, most patients receiving 
the additional application of pravastatin were selected by 
the principal investigators (B.G. and D.J.) after admission 
to the hospital. They represent a cohort of patients with 
advanced HCC suitable for treatment by transarterial 
chemoembolization. As illustrated in  table 1 , the 6 inde-
pendent predictors of survival according to VISUM-HCC 
were equally distributed between patients receiving 
TACE alone or combined with pravastatin. Thus, it is not 
likely that a selection bias has affected the outcome of the 
study (survival time). 
 The success of chemoembolization relies on the fact 
that HCC derives its blood supply predominantly from 
the hepatic artery, whereas the surrounding liver receives 
both portal and arterial blood. Chemoembolization re-
quires catheterization of the segmental hepatic artery 
supplying the tumor and performance of an arterio-
gram.
 Chemotherapeutic agents are then injected intra-arte-
rially and the hepatic artery is then occluded by injection 
of material to obstruct the flow  [6, 7, 21] .
 The theoretical benefits of this approach include de-
livery of a high concentration of chemotherapy to the tu-
mor, a marked increase in contact time between drugs 
and tumor cells and high rates of first-pass extraction. 
Thus, the drugs are concentrated in the liver and tumor 
while systemic effects are minimized. However, chemo-
embolization is generally considered as palliative treat-
ment because it does not achieve complete necrosis of the 
tumor.
 Thus, our patients treated with chemoembolization 
alone showed a less favorable prognosis in the long term. 
As illustrated in  figure 1 , within the first year the sur-
vival is about 50%, but only a few patients survived to the 
end of the 3-year follow-up. 
 Drug resistance is one of the major problems of che-
motherapy, which causes treatment failure and leads to 
progressive disease  [22] . Potential mechanisms of resis-
tance to cytotoxic drugs include the activation of the Ras/
Raf/MEK/ERK signal transduction cascade  [11] and the 
increase of cholesterol levels in cancer cells  [23, 24] . The 
enzyme 3-hydroxy-3-methylglutaryl coenzyme-A reduc-
tase (HMG-CoAR) is known to catalyze, the rate-limit-
ing step in the mevalonate pathway, leading to the pro-
duction of isoprenoids. Isoprenoids are involved both in 
the activation of Ras and in cholesterol synthesis  [25] . 
Thus, HMG-CoAR is a rational molecular target for in-
novative antineoplastic treatment of HCC. 
 In addition to their cholesterol-lowering effects, statins 
such as fluvastatin and pravastatin inhibit tumor cell 
growth  [11–14] . Statins have also been shown to synergis-
tically enhance the effects of chemotherapy and to over-
come chemoresistance  [26–33] . Moreover, morbid obe-
sity has been shown to be associated with increased cho-
lesterol and HMG-CoAR levels and with liver cancer  [34, 
35] . Accordingly, HMG-CoAR inhibition by pravastatin 
prolonged the survival of patients with advanced HCC in 
a randomized clinical trial  [16] .
 Several preclinical trials confirm an anticancer effi-
cacy of statins, investigating the mechanisms leading to 
growth inhibition  [36] . In a recent study, Sutter et al.  [22] 
showed that HMG-CoAR inhibitors decreased the prolif-
eration of HCC cells by inducing apoptosis and cell cycle 
arrest. The authors suggest that the inhibition of HMG-
CoAR by statins is a promising novel approach for the 
treatment of HCC that warrants further evaluation. This 
has been done in our study and our data show that pa-
tients with advanced HCC have a more favorable long-
term survival if combined treatment with chemoemboli-
zation and pravastatin is administered. These results are 
in accordance with the previous randomized controlled 
trial and support a wider application of pravastatin in 
HCC patients selected for chemoembolization.
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